Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Aurobindo plans to...

    Aurobindo plans to launch 19 drugs in US in next 3 quarters

    Written by savita thakur thakur Published On 2016-09-05T14:44:25+05:30  |  Updated On 5 Sept 2016 2:44 PM IST
    Aurobindo plans to launch 19 drugs in US in next 3 quarters

    New Delhi : Homegrown pharmaceuticals firm Aurobindo Pharma expects to launch 19 approved products that have an addressable market of USD 6.8 billion in the US in the next three quarters.


    "We have 19 product families that are approved, that will be launched over the next three quarters and that is for approvals that we have on hand today," Aurobindo Pharma USA CEO Robert Cunard told analysts.


    He further said the company has another 22 targeted "action dates through the end of the fiscal year" although it does not "anticipate all those will be final approvals but a significant number will be".


    In terms of the potential of the product pipeline, Cunard said: "And of that 19 product families today, the addressable market is about USD 6.8 billion as per IMS June data."


    While a large portion of that is Esomeprazole, still "a lot of breadth remains in that pipeline and we think that accelerates through the balance of the fiscal year", he added.


    Cunard said Aurobindo is trying to focus and ensure maintainers of service levels, introduce the products and get the most out of the launches.


    In terms of preparedness on the manufacturing side, he said although the company had "some catching up to do as far as validation and manufacturing" is concerned , it is "in a good position with that now, the facilities have been able to step up and we are in a good position to launch those over the next three quarters."


    Commenting on the over the counter (OTC) segment in the US, Aurobindo Pharma MD N Govindarajan said the company expects a spurt in growth in the second half of 2017-18.


    "Right now, it (OTC) is still less than USD 10 million in terms of the current sale. As you would appreciate the fact that at the end of the day you need to have a critical mass in terms of the market before you really grow in this business," he said.


    "As far as products(are concerned), we have 20 products in the (US) market under OTC segment," he added.

    approvalAurobindogrowthN GovindarajanOTCover-the-counterRobert Cunard
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok